Treatment Efficacy Research and Clinical Treatment

2003 ◽  
Vol 13 (1) ◽  
pp. 31-33
Author(s):  
Bruce P. Ryan
2020 ◽  
Vol 110 (2) ◽  
Author(s):  
Michael S. Nirenberg ◽  
Jai Saxelby ◽  
Rachel Vernon ◽  
Wesley Vernon

The practice of the clinical podiatrist traditionally focuses on the diagnosis and treatment of conditions of the foot, ankle, and related structures of the leg. Clinical podiatrists are expected to be mindful of “the principles and applications of scientific enquiry.” This includes the evaluation of treatment efficacy and the research process. In contrast, the forensic podiatrist specializes in the analysis of foot-, ankle-, and gait-related evidence in the context of the criminal justice system. Although forensic podiatry is a separate, specialized field, many aspects of this discipline can be useful in the clinical treatment and management of foot and ankle problems. The authors, who are forensic podiatrists, contend that the clinical podiatrist can gain significant insights from the field of forensic podiatry. This article aims to provide clinical podiatrists with an overview of the principles and methods that have been tested and applied by forensic podiatrists in their practice, and suggests that the clinical practice of the nonforensic foot practitioner may benefit from such knowledge.


Author(s):  
Gwendolyn E. Wood ◽  
Nicole L. Jensen ◽  
Sabina Astete ◽  
Jørgen S. Jensen ◽  
George E. Kenny ◽  
...  

Mycoplasma genitalium is a sexually-transmitted bacterium associated with non-gonococcal urethritis (NGU) in men and cervicitis, endometritis, and pelvic inflammatory disease in women. Effective treatment is challenging due to the inherent, and increasingly acquired, antibiotic resistance in this pathogen. In our treatment trial conducted from 2007 – 2011 in Seattle, WA, we demonstrated poor efficacy of azithromycin (AZM) and doxycycline (DOX) against M. genitalium among men with NGU. In the current study, we cultured M. genitalium from 74 of 80 (92.5%) PCR-positive men at enrollment (V-1), and defined the minimum inhibitory concentration (MIC) for AZM (N=56 isolates) and DOX (N=62 isolates). Susceptibility to AZM was bimodal; MICs were >8 μg/ml (44.6%) and <0.004 μg/ml (55.4%) for these isolates. The association of MIC with treatment efficacy was determined for men initially treated with either AZM (N=30) or DOX (N=24). Men treated with AZM were more likely to experience microbiologic treatment failure (p<0.001) if infected with isolates that had AZM MICs >8 μg/ml (18/18 men) as compared with isolates that had AZM MICs (1/12 men). Clinical treatment failure also was more likely to occur (p=0.002) with AZM MICs of >8 μg/ml (12/18 men) than with AZM MICs of <0.004 μg/ml (1/12 men). In contrast, DOX MICs ranged from <0.125 to 2 μg/ml and were not correlated with microbiologic (p=0.71) nor clinical treatment failure (p=0.41), demonstrating no relationship between DOX MICs and treatment efficacy. Given the rapid spread of AZM resistance and the emergence of quinolone resistance, the current second-line therapy, monitoring MICs and evaluating other potential treatments for M. genitalium will be critical.


1996 ◽  
Vol 39 (1) ◽  
pp. 221-222 ◽  
Author(s):  
David Snow ◽  
Linda Swisher ◽  
Mary McNamara ◽  
Barbara Kiernan

Sign in / Sign up

Export Citation Format

Share Document